Open AccessHarmonizing Heterogeneous Endpoints in Coronavirus Disease 2019 Trials Without Loss of Information
Author(s) -
Maja von Cube,
Marlon Grodd,
Martin Wolkewitz,
Derek Hazard,
Tobias Wengenmayer,
Emmanuel Canet,
Jérôme Lambert
Publication year - 2020
Publication title -
critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.002
H-Index - 271
eISSN - 1530-0293
pISSN - 0090-3493
DOI - 10.1097/ccm.0000000000004741
Subject(s) - medicine , clinical trial , disease , clinical endpoint , randomized controlled trial , coronavirus , intensive care medicine , surrogate endpoint , infectious disease (medical specialty) , covid-19
Many trials investigate potential effects of treatments for coronavirus disease 2019. To provide sufficient information for all involveddecision-makers (clinicians, public health authorities, and drug regulatory agencies), a multiplicity of endpoints must be considered. The objectives are to provide hands-on statistical guidelines for harmonizing heterogeneous endpoints in coronavirus disease 2019 clinical trials.